ImmunoGen Articles
US FDA approves Roche's late-stage breast cancer drug Kadcyla
25 February 2013
Licensing deals for Amgen/ImmunoGen and Shire/Arrowhead
20 December 2012
More highlights from ESMO Congress
2 October 2012
ImmunoGen inks ADC cancer deal with Lilly
21 December 2011
Sanofi pays $3 million milestone to ImmunoGen on start of SAR3419 Ph II testing; FDA accepts Aubagio filing
21 October 2011
ImmunoGen earns $2 million milestone from Bayer
16 June 2011
ImmunoGen collaborates with Novartis on cancer drugs for $45 million upfront, plus potential $200 million per target; updates financials
12 October 2010
Showing 1-8 of 8 articles
- 1
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
